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SuMMAry – Opioids are considered the cornerstone of pain management in palliative care. 
Available data suggest that older patients use different analgesics and lower opioid doses compared to 
younger patients. however, it has not been elucidated yet whether such dosing is associated with worse 
pain levels or shorter survival in the palliative care setting. we evaluated the relationship among pain 
scores, quality of life, opioid dose, and survival in palliative care cancer patients in a hospice setting. A 
total of 137 palliative care cancer patients were analyzed prospectively. we divided patients into two 
groups using the age of 65 as a cut-off value. younger patients exhibited significantly higher pain rat-
ings (5.14 vs. 3.59, p=0.01), although older patients used almost 20 mg less oral morphine equivalent 
(OMe) on arrival (p=0.36) and 55 mg OMe/day less during the last week (p=0.03). There were no 
differences in survival between the two groups (17.36 vs. 17.58 days). The elderly patients also used 
nonsteroidal analgesics less often and paracetamol more often. hence, using lower opioid doses in 
older palliative care cancer patients does not result in worse pain rating, and could be a plausible ap-
proach for pain management in this patient group.
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Introduction
treatment of pain is one of the most important 
goals of palliative care, with opioids considered one of 
the four essential drugs in the care of the dying, along 
with antipsychotics, anxiolytics, and antimuscarinics1. 
however, the use of opioids in the hospice setting is a 
controversial issue, as studies have shown that opioid 
use is associated with both longer and shorter surviv-
al2,3, whereas some researchers demonstrated no effect 
of opioids on survival4. Opioids, however, remain the 
cornerstone of pain management in palliative care, 
while the use of non-opioid analgesia is rarely recom-
mended, partly due to the potentially life-threatening 
side effects, especially in patients with many comor-
bidities5. despite these recommendations and lack of 
research demonstrating their safety, nonsteroidal anti-
inflammatory drugs (nSAid) and paracetamol are 
still among the most commonly used drugs in the care 
of the dying6,7.
Along with controversies regarding the choice of 
analgesics, there are indications that elderly palliative 
care patients require different pain management than 
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younger patients due to decreased renal excretion and 
hepatic metabolism, greater number of comorbidities, 
and higher risk of polypharmacy and adverse drug ef-
fects. Additionally, although some researchers suggest 
that older patients experience similar or even less pain 
than younger patients, pain management in the elderly 
is often unsatisfactory8-15.
in our previous retrospective study conducted in 
the same hospice, we found older patients to have used 
lower opioid doses and suggested opiophobia or lower 
needs of opioids in the elderly due to altered opioid 
metabolism as the possible culprits16-18. Our findings 
were supported by a similar research, which found that 
the elderly experienced similar pain intensity as 
younger patients but required up to 71 mg less of par-
enteral morphine equivalent a day19. however, the re-
search was retrospective and did not evaluate differ-
ences in survival or use of additional or adjuvant anal-
gesics20, which could explain the need for lower opioid 
doses.
in this research, we tried to answer the question of 
whether the use of lower opioid doses in elderly cancer 
patients is associated with worse pain levels and qual-
ity of life.
Patients and Methods
The study was conducted in Marija Krucifiksa 
Kozulić hospice in rijeka, Croatia, which is the only 
hospice in the country and hosts 14 beds. The research 
was part of a larger study and was performed from 
September 2016 until August 2017. we included 137 
patients who had to be over age 18 and had to sign an 
informed consent. exclusion criteria included deliri-
um, unable or refusing to provide informed consent, or 
cognitive state that prevented appropriate evaluation 
of pain scales. All the patients had undergone special-
ist evaluation according to which no active treatment 
was left anymore and life expectancy was less than 
three months. Although there is no universal defini-
tion of the elderly, we used 65 years of age as a typical 
cut-off value to define elderly patients21. The hospice 
ethics Committee approved this research, which was 
performed in line with the highest medical and ethical 
standards.
The patients were evaluated within the first two 
days of admission. The evaluation consisted of the eu-
ropean Organization for research and treatment of 
Cancer Quality of life Questionnaire Core 15 Pal 
(eOrtC QlQ-C15-PAl) and edmonton Symp-
tom Assessment System (eSAS)22,23. demographic 
data and the Palliative Performance Scale (PPS) were 
recorded from the charts. Only the subset score from 
the pain and quality of life variables on both question-
naires were included in this analysis24. eSAS is an 11-
item scale, where 0 denotes no pain and 10 denotes the 
worst possible pain. eOrtC QlQ-C15-PAl esti-
mates the frequency of pain during the week prior to 
examination, ranging from 1 (not at all) to 4 (very 
much).
Medications analyzed further in the text were pre-
scribed on schedule and were extracted from medical 
charts. Opioid doses were converted to the oral mor-
phine equivalents (OMe, mg/day), while corticoste-
roid doses were converted to methylprednisolone 
equivalent doses25,26. we did not analyze difference in 
the doses of anxiolytics, nSAids or antidepressants 
due to difficulties with calculating equivalent doses 
and differences in half-life.
descriptive statistics was used to analyze demo-
graphic data and included means, medians, and stan-
dard deviations. Mann whitney test was used to de-
termine differences between patient groups. The χ2-
test was used to test differences in frequency between 
the groups, while differences in survival were assessed 
using the log-rank test and Kaplan-Meier method. All 
statistical procedures were performed by use of Statis-
tica 12 software (StatSoft, tulsa, uSA).
Results
A total of 137 cancer patients were included in the 
study, 78 male and 59 female patients, mean age 71.8±9.3 
years. The patients were divided into younger and older 
patient groups, using age 65 as the cut-off value. The 
most common cancers were lung (n=34, 24.8%), gastro-
intestinal (n=25, 18.2%) and hepatobiliary cancers 
(n=17, 12.4%). lung and gastrointestinal cancers were 
most common in both groups of patients, although the 
third most common cancer in younger patients was uro-
logic cancer (n=4, 14.3%). There were no significant dif-
ferences between the two groups according to PPS, gen-
der, level of education, discharge status, metastatic sta-
tus, whether pain was present upon arrival, or number of 
days spent in the hospice (17.36 vs. 17.58 days in 
younger and older patients, respectively) (table 1).
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no differences were recorded in the pain and qual-
ity of life subset scores in the eOrtC QlQ-C15 
PAl and the wellbeing score in the eSAS. however, 
younger patients reported significantly higher pain 
ratings measured on the eSAS questionnaire (5.14 vs. 
3.59, p=0.01) (table 2).
On admission, the most commonly used opioids in 
regular therapy were tramadol (n=58), fentanyl trans-
dermal patches (n=45), buprenorphine transdermal 
patches (n=20) and oral morphine (n=14), while 
paracetamol (n=39), ibuprofen (n=13) and diclofenac 
(n=4) were the most commonly used non-opioid anal-
gesics. On average, older patients used almost 20 mg 
OMe/day less on admission (p=0.36) and 55 mg 
OMe/day less during the last week (p=0.03) as com-
pared with younger patients. Additionally, fewer older 
patients used opioids at all, both on admission (68.8% 
vs. 85.7%) and during the last week (75.2% vs. 89.3%), 
Table 1. Demographic data (N=137)
All patients younger patientsa Older patientsa
number of patients (%) 137 (100) 28 (20.4) 109 (79.6)
Mean age, years (±Sd) 71.8 (9.3) 58.6 (6.7) 75.2 (6.3)
PPS (±Sd) 33.1 (12.5) 37.1 (15.6) 32.1 (11.5)
number of days in hospice (±Sd) 17.54 (19.7) 17.36 (19.8) 17.58 (19.8)
Gender
female (%) 59 (43.1) 11 (39.3) 48 (44.0)
Level of education
elementary (%) 35 (25.6) 5 (17.9) 30 (27.5)
high school (%) 74 (54.0) 17 (60.7) 57 (52.3)
College (%) 24 (17.5) 6 (21.4) 18 (16.5)
not specified (%) 4 (2.9) 0 (0) 4 (3.7)
Metastatic status
Metastasis present (%) 109 (79.6) 24 (85.7) 85 (77.9)
Discharge status
death (%) 115 (83.9) 22 (78.6) 93 (85.3)
discharged (%) 22 (16.1) 6 (21.4) 16 (14.7)
Pain present on admission
yes (%) 72 (52.6) 16 (57.1) 56 (51.4)
no (%) 64 (46.7) 12 (42.9) 52 (47.7)
unknown 1 (0.7) 0 (0) 1 (0.9)
aBased on the cut-off value of 65 years of age; PPS = Palliative Performance Scale
Table 2. Pain and quality of life scores on admission (N=137)
Category All patients youngerc Older* p-value
Pain, QlQ-C15-PAl subset, mean ± Sd 55.59±25.82 60.71±29.82 54.28±24.68 0.24
Quality of life, QlQ-C15-PAl subset, mean ± Sd 32.35±18.34 30.95±21.14 32.72±17.64 0.65
Pain, eSAS subset, mean ± Sd 3.86±2.58 5.14±2.33 3.59±2.55 0.01
wellbeing, eSAS subset, mean ± Sd 6.74±1.85 7.13±1.79 6.65±1.89 0.27
QlQ-C15-PAl subset = Quality of life Questionnaire Core 15 PAl, from 0 to 100, higher values indicate higher level of pain or higher 
quality of life; eSAS subset = edmonton Symptom Assessment System, from 0 to 10, higher values indicate higher level of pain or lower 
wellbeing; *based on the cut-off value of 65 years of age; Sd = standard deviation; bold figure denotes statistical significance
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although the difference did not reach statistical sig-
nificance (table 3).
elderly cancer patients used nSAids less often, 
both initially (28.6% vs. 11.0%, p=0.02) and in the last 
week (28.6% vs. 12.8%, p=0.04), while they used 
paracetamol more often at both time points (10.7% vs. 
33.0%, p=0.02 initially, and 10.7% vs. 32.1%, p=0.02 
during the last week). There were no differences in the 
dosage of paracetamol (1083 mg/day vs. 994 mg/day, 
p=0.80), haloperidol (2.92 vs. 2.41 mg/day, p=0.59), or 
methylprednisolone equivalent doses (30.5 mg vs. 50.1 
mg, p=0.18) between the younger and older patient 
groups. even when observing the whole study popula-
tion, there was positive correlation of r=0.245 (p<0.05) 
between age and the initial opioid dose. There was no 
between-group difference in the frequency of using 
corticosteroids, antipsychotics, anxiolytics and antide-
pressants, either on admission or during the last week 
(table 3).
There was a correlation between the quality of life 
and pain score in both eOrtC QlQ-C15 PAl (r= 
-0.31) and eSAS (r=0.5) (p<0.05). interestingly, the 
higher opioid dose was associated with worse pain rat-
ings on both eSAS (r=0.31, p<0.05) and eOrtC 
QlQ-C15 PAl (r=0.28, p<0.05). The use of pain 
medication also seemed to form a pattern, as the use of 
paracetamol and nSAids showed a significant nega-
tive association (r=-0.21), while the use of paracetamol 
showed a positive correlation to opioid use (r=0.32). 
no association was found between the use of nSAids 
and opioids (r=0.02).
regarding difference in survival, the patients that 
used nSAids on admission had longer survival com-
pared to patients who did not (26.7 vs. 15.9 days, 
p=0.001), while no difference was recorded for para-
cetamol use (14.9 vs. 18.6 days, p=0.72).
Discussion
Concerning the use of opioids, paracetamol and 
nSAids, they all have controversies in palliative care 
due to fear of the potentially life-threatening side ef-
Table 3. Use of analgesics (N=137)
Category All patients youngera Older* p-value
Opioids
OMe mg/day on arrival, mean (mean ± Sd) 100.21 (92.18) 115.19 (83.39) 95.42 (94.85) 0.36
OMe mg/day in last week, mean (mean ± Sd) 122.96 (115.06) 165.61 (142.22) 109.95 (102.95) 0.03
Classical analgesics
Opioids, initial (%) 99 (72.3) 24 (85.7) 75 (68.8) 0.07
Opioids, final (%) 107 (78.1) 25 (89.3) 82 (75.23) 0.11
Paracetamol, initial (%) 39 (28.5) 3 (10.7) 36 (33.0) 0.02
Paracetamol, final (%) 38 (27.7) 3 (10.7) 35 (32.1) 0.02
nSAid, initial (%) 20 (14.6) 8 (28.6) 12 (11.0) 0.02
nSAid, final (%) 22 (16.1) 8 (28.6) 14 (12.8) 0.04
Adjuvant analgesics
Corticosteroids, initial (%) 40 (29.2) 8 (28.6) 32 (29.4) 0.93
Corticosteroids, final (%) 45 (32.8) 9 (32.1) 36 (33.0) 0.93
Antipsychotics, initial (%) 29 (21.2) 6 (21.4) 23 (21.1) 0.97
Antipsychotics, final (%) 44 (32.1) 9 (32.1) 35 (32.1) 0.99
Anxiolytics, initial (%) 83 (60.6) 17 (60.7) 66 (60.6) 0.99
Anxiolytics, final (%) 81 (59.1) 16 (57.1) 65 (59.6) 0.81
Antidepressants, initial (%) 21 (15.3) 6 (21.4) 15 (13.8) 0.32
Antidepressants, final (%) 22 (16.0) 6 (21.4) 16 (14.7) 0.39
OMe = oral morphine equivalent; nSAid = nonsteroidal anti-inflammatory drug; *based on the cut-off value of 65 years of age; Sd = 
standard deviation; bold figures denote statistical significance
M. Golčić et al. Treatment of pain in elderly palliative care cancer patients
Acta Clin Croat, Vol. 59, No. 3, 2020 391
fects. The use of opioids is lately under particular scru-
tiny due to the presence of major opioid crisis, and is 
reinforced by the fact that up to 25% of hospice pa-
tients have substance use disorders, often associated 
with the usage of higher levels of opioids27,28. however, 
treatment with opioids is dependent on the medico-
legal responsibilities of prescribers29, hence it may vary 
significantly among different populations.
Age is an important factor in pain management 
and choice of analgesics. Although only a few studies 
explored the issue, pain levels do not seem to be higher 
in older patients despite using lower doses of opioids. 
This phenomenon may be explained by the more ad-
vanced coping strategies, questionnaires being more 
sensitive in younger population, difference in the use 
of additional analgesics, as well as some specific cul-
tural factors8,15. Our previously published research on 
790 cancer patients in the same hospice showed that 
patients older than 65 used significantly less opioids 
on arrival as compared with younger patients (146.2 
vs. 86.9 mg OMe/day); however, we did not analyze 
pain scores or quality of life16.
hence, in this study, we aimed to answer the ques-
tion of whether using fewer opioids is associated with 
higher pain levels or worse quality of life in the elderly. 
we used the definition of the elderly as people older 
than 65, although we recognize the need to update that 
definition, especially in the areas such as palliative care26.
Both groups of patients had very similar demo-
graphic characteristics (table 1). younger patients re-
ported higher levels of pain compared to older patients, 
although no differences were found in the quality of 
life scores. regarding the use of analgesics, there was a 
trend showing the older cancer patients to have used 
opioids less frequently (85.7% vs. 68.8%) and in lower 
doses (115 mg vs. 95 mg OMe/day) but the difference 
did not reach statistical significance in this population. 
The difference in the doses of opioids between the 
groups reached significance during the last week (165 
vs. 109 mg OMe/day), although no data are available 
on pain scores. There were no differences in the use of 
anxiolytics, antipsychotics, or corticosteroids between 
the two groups either. however, we did show that the 
elderly used nSAids significantly less often (28.6 vs. 
11.0%) and paracetamol significantly more often 
(33.0% vs. 10.7%), although there was no difference in 
the dose of paracetamol. Such results suggest that the 
use of paracetamol might be a plausible option for se-
lected elderly cancer patients instead of opioids or 
nSAids.
despite differences in pain management, there 
were no differences in discharge status or survival be-
tween the two groups (table 1). Additionally, although 
nSAids are not recommended frequently in the ter-
minal phase due to their side effects such as cardiotox-
icity and gastrointestinal bleeding, we did not find 
shorter survival either with these analgesics or with 
paracetamol13. Such findings could suggest that these 
drugs are safe to use in a hospice setting for selected 
patients, although the lack of information regarding 
renal or hepatic comorbidities might significantly in-
fluence our results.
There are certain limitations of the study that we 
must address. we performed a single-center study on 
Caucasian patients, and due to the concept of the study, 
we could not assess causality but only association. Ad-
ditionally, we have no data regarding renal or hepatic 
reserve, since invasive measures including drawing 
blood are rarely used in a hospice setting, and only a 
minority of patients present recent blood analysis re-
sults. This information could significantly impact sur-
vival, especially in patients using nSAids, but was un-
available in our hospice population. A selection bias was 
also present, as less than 50% of patients were eligible to 
participate in the study or were well enough for ques-
tionnaire assessment. however, our data could be used 
to generate hypotheses and design a prospective study.
Conclusion
Our data suggest that there is a difference in pain 
management between younger and older cancer pa-
tients. Older patients used opioids and nSAids less 
often and paracetamol more often. however, younger 
patients reported worse pain scores, with no difference 
in the quality of life or survival. hence, the data sug-
gest that the principle “start low, go slow” must be used 
on opioid titration in the elderly14 and that the use of 
paracetamol could be a plausible option for pain con-
trol in selected cancer patients instead of opioids.
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Sažetak
treBAMO li liJeČiti BOl u StAriJih PAliJAtivnih OnKOlOŠKih BOleSniKA druKČiJe?
M. Golčić, R. Dobrila-Dintinjana, G. Golčić, I. Plavšić, L. Gović-Golčić, B. Belev, D. Gajski i K. Rotim
Opioidi se smatraju jednim od osnovnih lijekova u liječenju boli u palijativnoj skrbi. dostupni podaci ukazuju na to da 
stariji bolesnici uzimaju drukčije analgetike uz niže doze opioida u usporedbi s mlađim bolesnicima. Međutim, nije razjaš-
njeno utječe li takvo doziranje opioida na lošije liječenje razine boli ili kraće preživljenje u uvjetima palijativne skrbi. Anali-
zirali smo odnos razine boli, kvalitete života, doze opioida i preživljenja u palijativnih onkoloških bolesnika koji su bili hos-
pitalizirani u hospiciju. ukupno je 137 palijativnih bolesnika analizirano prospektivno. Bolesnici su podijeljeni u dvije skupi-
ne pri čemu se dob od 65 godina uzimala kao granica između skupina. Mlađi bolesnici su izražavali višu razinu boli prilikom 
dolaska u hospicij (5,14 prema 3,59, p=0,01), iako su stariji bolesnici koristili gotovo 20 mg manje oralnog morfij ekvivalen-
ta (OMe) na dan dolaska te čak 55 mg OMe manje na dan tijekom zadnjeg tjedna (p=0,03). nije bilo razlika u preživljenju 
između dviju skupina bolesnika (17,36 prema 17,58 dana). Starija skupina bolesnika također je nesteroidne antireumatike 
uzimala rjeđe, a paracetamol češće od mlađe skupine. uzimanje nižih doza opioida u starijih onkoloških bolesnika u palija-
tivnoj skrbi nije rezultiralo lošijom razinom boli pa bi to mogao biti razuman pristup liječenju boli u ovoj skupini bolesnika.
Ključne riječi: Stariji bolesnici; Hospicijska skrb; Opioidi; Liječenje boli; Palijativna skrb
